EBV-coded latent proteins: function, recognition by cytotoxic T cells, and expression in the EBV infectious cycle and lymphoid tumors
. | . | . | Gene expression program/tumor type . | . | . | ||
|---|---|---|---|---|---|---|---|
| Latent protein . | Main function . | CTL recognition . | Growth program/PTLD . | Default/HD . | Latency/BL* . | ||
| EBNA | |||||||
| 1 | Genome maintenance | +/– | + | + | + | ||
| 2 | Viral transactivator | + | + | – | – | ||
| 3A | EBNA 2 antagonist; disrupts cell cycle | ++ | + | – | – | ||
| 3B | EBNA 2 antagonist | ++ | + | – | – | ||
| 3C | EBNA 2 antagonist; disrupts cell cycle | ++ | + | – | – | ||
| Leader protein | Cooperates with EBNA 2 | +/– | + | – | – | ||
| LMP | |||||||
| 1 | Viral oncogene; survival factor | + | + | + | – | ||
| 2A,B | Survival factor | + | + | + | – | ||
. | . | . | Gene expression program/tumor type . | . | . | ||
|---|---|---|---|---|---|---|---|
| Latent protein . | Main function . | CTL recognition . | Growth program/PTLD . | Default/HD . | Latency/BL* . | ||
| EBNA | |||||||
| 1 | Genome maintenance | +/– | + | + | + | ||
| 2 | Viral transactivator | + | + | – | – | ||
| 3A | EBNA 2 antagonist; disrupts cell cycle | ++ | + | – | – | ||
| 3B | EBNA 2 antagonist | ++ | + | – | – | ||
| 3C | EBNA 2 antagonist; disrupts cell cycle | ++ | + | – | – | ||
| Leader protein | Cooperates with EBNA 2 | +/– | + | – | – | ||
| LMP | |||||||
| 1 | Viral oncogene; survival factor | + | + | + | – | ||
| 2A,B | Survival factor | + | + | + | – | ||
CTL indicates cytotoxic T lymphocyte; PTLD, posttransplantation lymphoproliferative disease; HD, Hodgkin disease; BL, Burkitt lymphoma; EBNA, EB nuclear antigen; +, positive; –, negative; and LMP, latent membrane protein.
EBNA1 only expressed in dividing memory B cells